BioStock Studio: Cyxone comments on the Covid-19 study results

Biotech company Cyxone has announced results from their phase II trial with drug candidate Rabeximod in patients with moderate to severe Covid-19. The data were inconclusive in terms of the effect of the drug candidate compared to standard of care treatment and Cyxone will now analyse the results further. In parallel, the company is preparing Rabeximod for a coming phase II trial in rheumatoid arthritis, the main focus for the candidate and Cyxone’s leading project. Tara Heitner, CEO, and Carl-Magnus Högerkorp, COO, visited the BioStock Studio to explain.

Watch the interview with Cyxone at biostock.se:

https://www.biostock.se/en/2021/12/biostock-studio-cyxone-comments-on-the-covid-19-study-result/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/